Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPE

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEUs) under the ACPE universal activity number 0290-9999-19-206-H01-P. The activity is available for CE credit through October 23, 2020.

For Pharmacists, please click here to participate in this activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Sanofi Genzyme.

Neurology Consultations™: Coordinating Care Between the Neurologist and Pharmacist in Multiple Sclerosis Treatment

Release Date: October 23, 2019
Expiration Date: October 23, 2020
Media: Internet - based

Activity Overview

This activity features the Neurology Consultations™ platform, consisting of video clips featuring the latest clinical updates and case-based conversations between a neurologist and a pharmacist who specialize in the care of patients with multiple sclerosis (MS). This online educational activity features 3 patient case scenarios addressing topics such as family planning in the era of disease-modifying therapies (DMTs), magnetic resonance imaging (MRI) as a tool to inform clinical decisions, opportunities for patients who fail platform therapies, and other pertinent clinical issues in multiple sclerosis.

Benefits of Participating

  • Hear experts discuss real patient case scenarios
  • Learn something new and improve your clinical practice
  • Be inspired to converse with other specialists to improve care
  • Get answers to questions surrounding complicated clinical scenarios

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Video” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This activity is intended for neurologists and pharmacists, as well as physician assistants, nurse practitioners, primary care physicians, and nurses, involved in the diagnosis, management, and treatment of MS.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Recognize the importance of early diagnosis and treatments of MS using efficacious DMT
  • Describe best practices for effective communication and coordination between specialty pharmacists and neurologists to optimize patient outcomes
  • Analyze data from recent clinical trials to determine the role of novel DMTs in the existing treatment landscape and the potential for improving clinical outcomes

Faculty, Staff, and Planners’ Disclosures

Faculty

Joseph R. Berger
Joseph R. Berger, MD
Professor of Neurology
Hospital of the University of Pennsylvania
Department of Neurology
Associate Chief of the Multiple Sclerosis Division
Perelman School of Medicine
Philadelphia, PA

Disclosures: Grant Research Support: Biogen, Genentech; Consultant: Biogen, Novartis, Sanofi/Genentech, Millennium/Takeda, Genzyme, Inhibikase, Excision BioTherapeutics, Celgene, Shire, Merck, Serono, Encycle, Finnstat, Amgen.

Ryan Fuller
Ryan Fuller, PharmD
Clinical Pharmacy Specialist
Department of Pharmacy
MS Division
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Ryan Fuller, PharmD, has no relevant financial relationships with commercial interest to disclose.

Pharmacy Times Continuing Education™
Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Olivia Mastrodonato; Susan Pordon, and Brianna Winters.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and a nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse™ Recaps

1 of 3

In this online continuing medical education‒certified activity, Neurology Consultations™: Coordinating Care Between the Neurologist and Pharmacist in Multiple Sclerosis Treatment, expert faculty Joseph R. Berger, MD, and Ryan Fuller, PharmD, discuss the important relationship between a neurologist and a pharmacist when caring for patients with a multiple sclerosis (MS) diagnosis, with perspectives on early diagnosis; highly efficacious treatment of active MS; and the most current data on efficacy, safety, and dosing and administration of approved MS therapies.

This first of 3 PER Pulse™ Recaps summarizing the webcast focuses on diagnosing MS and approaching the care of women of childbearing age. Below are highlights of the topics covered during the activity featuring our experts.

  • Patient characteristics and clinical features indicating the probability of MS
  • Appropriate MS therapies and important considerations in family planning
  • Managing a patient’s expectations and improving quality of life

“It’s important that you feel comfortable with the diagnosis before initiating therapy [for] a patient [of childbearing age] and ruling out diseases [that] may mimic MS, and establishing that the patient fulfills McDonald criteria is incredibly helpful.”

—Joseph R. Berger, MD


2 of 3

As a follow-up to this online continuing medical education‒certified activity, Neurology Consultations™: Coordinating Care Between the Neurologist and Pharmacist in Multiple Sclerosis Treatment, expert faculty Joseph R. Berger, MD, and Ryan Fuller, PharmD, discuss a patient with a diagnosis of relapsing-remitting multiple sclerosis (MS).

This second of 3 PER Pulse™ Recaps summarizing the webcast focuses on therapeutic options for patients who fail platform therapy. Below are highlights of the topics covered during the activity featuring our experts.

  • Goals of therapy after a patient has failed platform therapy
  • Use of magnetic resonance imaging findings to guide clinical decisions
  • Barriers to treatment for patients with MS
  • Importance of a comprehensive medication review before initiating a new therapy
  • Best practices for patient education of their treatment
  • Strategies and interventions that can help improve patient adherence to therapy

“One of the other pieces to this is the cost of the medication. As we know, all these medications are very expensive, and if a patient can’t afford the therapy, it’s going to become a barrier to their treatment. The manufacturers provide some assistance to patients, and there’s also assistance through nonprofit organizations for Medicare patients. But that conversation has to happen with these patients to make sure that they are eligible and that eventually they’ll be able to pay for these medications.”

—Ryan Fuller, PharmD


3 of 3

As a final follow-up to this online continuing medical education‒certified activity, Neurology Consultations™: Coordinating Care Between the Neurologist and Pharmacist in Multiple Sclerosis Treatment, expert faculty Joseph R. Berger, MD, and Ryan Fuller, PharmD, discuss a case of progressive multiple sclerosis (MS) with worsening symptoms.

This third of 3 PER Pulse™ Recaps summarizing the webcast focuses on the importance of a multidisciplinary care team, especially in the setting of active and progressive disease. Below are highlights of the topics covered during the activity featuring our experts:

  • Emphasis on the importance of early diagnosis and aggressive treatment
  • Role of the clinical specialty pharmacist in optimizing MS care
  • Coordinating care between members of a comprehensive care team

“The barriers are finding the time of the physician and the patient to see the necessary [providers], and if it could all be done at the time of 1 office visit, it would be enormously beneficial for the patient and for the physician as well. I think as we evolve toward disease-based treatment models, we are likely to see a change in the formula of an MS clinic, and it will incorporate more of the general medical care for the patient than is generally routine.”

—Joseph R. Berger, MD


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By